The adjuvant potential of synthetic alkylglycerols

Vaccine

Volumn 24, Issue SUPPL. 2, 2006, Pages S32-

  Acevedo, Reinaldo ^a   Gil, Danay ^a   Campo, Judith Del ^a   Bracho, Gustavo ^a   Valdés, Yolanda ^b   Pérez, Oliver ^a  

^a FINLAY INSTITUTE   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

Author keywords

Adjuvant; Alkylglycerol; Vaccine

Indexed keywords

DECILGLICEROL; GLYCEROL DERIVATIVE; GLYCEROL DODECYL ETHER; HEXADECILGLICEROL; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; NITRIC OXIDE; OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 33645220949     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.109     Document Type: Article

References (4)

1. N. Yamamoto, D.A. St Claire, J.R. Homma, and B.Z. Ngwenga Activation of mouse macrophages by alkylglycerols Cancer Res 48 21 1988 6044 6049
2. W. Niedbala, X.Q. Wei, and F.Y. Liew Effects of nitric oxide on the induction and differentiation of Th1 cells Eur. J. Immunol. 29 1999 2498 2505
3. R.L. Coffman, VarkilaK, and P. Scott Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo Immunol Rev 123 1991 189 207
4. O. Perez, M. Lastre, and G. Bracho Immune response induction and new effector mechanism involved in protection conferred by the Cuban antimeningococcal BCVaccine Infect Immun 69 2001 24 31